Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets

被引：18

作者：

dos Santos Fernandes, Guilherme Felipe ^{[1
]}

Jornada, Daniela Hartmann ^{[1
]}

de Souza, Paula Carolina ^{[1
]}

Chin, Chung Man ^{[1
]}

Pavan, Fernando Rogerio ^{[1
]}

dos Santos, Jean Leandro ^{[1
]}

机构：

[1] Univ Estadual Paulista, UNESP, Fac Ciencias Farmaceut, Araraquara, Brazil

来源：

CURRENT MEDICINAL CHEMISTRY | 2015年 / 22卷 / 27期

基金：

巴西圣保罗研究基金会;

关键词：

Antitubercular drugs; drug discovery; Mycobacterium tuberculosis; resistant tuberculosis; tuberculosis; tuberculosis targets; KILLS MYCOBACTERIUM-TUBERCULOSIS; BIOLOGICAL EVALUATION; ANTIMYCOBACTERIAL ACTIVITY; IN-VITRO; RIMINOPHENAZINE DERIVATIVES; SIDEROPHORE BIOSYNTHESIS; RESISTANT TUBERCULOSIS; MOLECULAR-PROPERTIES; INHIBITORS; DESIGN;

D O I：

10.2174/0929867322666150818103836

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Tuberculosis (TB) is an infectious disease caused by bacterium of the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization aims to substantially reduce the number of cases in the coming years; however, the increased number of multidrug-resistant (MDR) and extremely drug-resistant (XDR) forms of the bacterium and the lack of treatment for latent tuberculosis are challenges to be overcome. In this review, we have identified the most potent compounds described in the literature during recent years with MIC values <7 mu M, low toxicity and a high selective index. In addition, emerging targets in MTB are presented to provide new perspectives for the discovery of new antitubercular drugs. This review aims to summarize the current advances in and promote insights into antitubercular drug discovery.

引用

页码：3133 / 3161

页数：29

共 50 条

[31] Recent advances of quinones as a privileged structure in drug discovery
Zhang, Li
Zhang, Guiying
Xu, Shujing
Song, Yuning
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 223
[32] Editorial: Tuberculosis Drug Discovery & Development: Drug Targets, Chemical Matter, and Approaches
Singh, Vinayak
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
[33] Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances
Scarim, Caue B.
Chin, Chung M.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2019, 22 (08) : 509 - 520
[34] Fluorescence lifetime assays: current advances and applications in drug discovery
Pritz, Stephan
Doering, Klaus
Woelcke, Julian
Hassiepen, Ulrich
EXPERT OPINION ON DRUG DISCOVERY, 2011, 6 (06) : 663 - 670
[35] Pangenome Analysis of Mycobacterium tuberculosis Reveals Core-Drug Targets and Screening of Promising Lead Compounds for Drug Discovery
Dar, Hamza Arshad
Zaheer, Tahreem
Ullah, Nimat
Bakhtiar, Syeda Marriam
Zhang, Tianyu
Yasir, Muhammad
Azhar, Esam I.
Ali, Amjad
ANTIBIOTICS-BASEL, 2020, 9 (11): : 1 - 14
[36] Cancer Metabolism: New Validated Targets for Drug Discovery
Sotgia, Federica
Martinez-Outschoorn, Ubaldo E.
Lisanti, Michael P.
ONCOTARGET, 2013, 4 (08) : 1309 - 1316
[37] Recent advances in drug discovery against Mycobacterium tuberculosis: Metal-based complexes
Scarim, Caue Benito
de Farias, Renan Lira
de Godoy Netto, Adelino Vieira
Chin, Chung Man
dos Santos, Jean Leandro
Pavan, Fernando Rogerio
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 214
[38] Recent Advances in Covalent Drug Discovery
Schaefer, Daniel
Cheng, Xinlai
PHARMACEUTICALS, 2023, 16 (05)
[39] Pyridones in drug discovery: Recent advances
Zhang, Yun
Pike, Andrew
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 38
[40] Molecular Docking: Principles, Advances, and its Applications in Drug Discovery
Muhammed, Muhammed Tilahun
Aki-Yalcin, Esin
LETTERS IN DRUG DESIGN & DISCOVERY, 2024, 21 (03) : 480 - 495

← 1 2 3 4 5 →